Novo Nordisk Patent Loss — Gold Rush for Indian Generic Pharma (Semaglutide)
9 Apr, 16:12 IST · Plays out over weeks · 1 source
Key facts
What the reporting establishes, before any reading of it.
- Novo Nordisk semaglutide patent lost/expired
- 13 companies launched 26 generic versions
- Massive addressable market in diabetes/obesity drugs globally
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Indian generic pharma companies with GLP-1 capabilities benefit massively
Who may gain
- NATCOPHARM, LUPIN, ZYDUSLIFE best positioned for generic semaglutide
Along the supply chain
Downstream
Pharmacies benefit from affordable alternatives
Upstream
API manufacturers for semaglutide intermediates see demand surge
Where demand moves
Business
Patent expiry opens floodgate - massive volume opportunity - Indian generic makers gain market share
Capital
Pharma becomes growth story - FII inflows to pharma names with GLP-1 pipeline
How it spreads across sectors
CDMO
Contract manufacturers benefit
Healthcare
Broader access to diabetes/obesity treatment
When it plays out
Immediate
Generic launches capture initial market share
Medium term
Indian generics dominate global semaglutide market
Short term
Price competition intensifies, volume ramps